Market Challenges And Opportunities

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Restraints

The major factors that hinder growth of the global genetic chronic obstructive pulmonary disease (COPD) market include that the development of new drugs is a challenging task and drug failures (termination) in clinical trials. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.

Increasing prevalence of chronic obstructive pulmonary disease (COPD), associated with awareness efforts carried out by individual organizations is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period.

Increasing prevalence of chronic obstructive pulmonary disease is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period. For instance, according to fact sheet published by World Health Organization in May 2022, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Moreover, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects a lot of people across the U.S. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.

Figure 2.Global genetic chronic obstructive pulmonary disease (COPD) Market Share (%), by Region, 2022

Global genetic chronic obstructive pulmonary disease (COPD) Market: Restraint

Increasing research and development activities and product launches for treatment of chronic obstructive pulmonary disease are expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth.

Increasing research and development activities by key players in market for the development of awareness and product launches is expected to drive the global genetic chronic obstructive pulmonary disease market growth. For instance, in June 2022, Verona Pharma, a pharmaceutical company, announced completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.

Moreover, Verona Pharma, a pharmaceutical company, in May 2019, commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe chronic obstructive pulmonary disease.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

However, the COVID-19 pandemic had a positive impact on the global genetic chronic obstructive pulmonary disease (COPD) market, owing to the increasing demand of drugs used in the treatment of chronic obstructive pulmonary disease in patients infected with COVID-19 infection. For instance, according to an article published by the National Center for Biotechnology Information, providing access to biomedical and genomic information, in February 2022, chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs, same dysfunction in lungs is observed in the patients infected with the coronavirus. The patients that are infected with coronavirus basically suffer from similar symptoms like breathing difficulty, insufficient supply of oxygen rich blood to lungs and overall body as in chronic obstructive pulmonary disease. Demand for drugs used in the treatment of chronic obstructive pulmonary disease increased as earlier in first wave of COVID-19 there was no particular drug therapy for treatment of COVID-19. The drugs used in treatment of chronic obstructive pulmonary disease were initially used in the treatment of coronavirus.